Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBIT Margin: 2022-2025

Historic EBIT Margin for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to 1,861.25%.

  • Centessa Pharmaceuticals' EBIT Margin rose 4642.00% to 1,861.25% in Q3 2025 from the same period last year, while for Sep 2025 it was -3,168.82%, marking a year-over-year decrease of 475661.00%. This contributed to the annual value of 1,992.62% for FY2024, which is 449200.00% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' EBIT Margin is 1,861.25%, which was down 1.78% from 1,895.04% recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' EBIT Margin registered a high of 4,138.78% during Q2 2022, and its lowest value of -205.18% during Q1 2025.
  • Over the past 3 years, Centessa Pharmaceuticals' median EBIT Margin value was 1,814.82% (recorded in 2024), while the average stood at 1,681.63%.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' EBIT Margin tumbled by 221,964bps in 2023, and later skyrocketed by 163,968bps in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' EBIT Margin (Quarterly) stood at 1,888.47% in 2022, then plummeted by 51,968bps to 1,368.79% in 2023, then surged by 163,968bps to 3,008.47% in 2024, then spiked by 4,642bps to 1,861.25% in 2025.
  • Its EBIT Margin stands at 1,861.25% for Q3 2025, versus 1,895.04% for Q2 2025 and -205.18% for Q1 2025.